Antiphospholipid Antibody and Risk of Retinal Vein Occlusion: a Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Apr 29

PMID 25918850

Citations 15

Authors

Wei Zhu

Yan Wu

Ming Xu

Jin-Yu Wang

Yi-Fang Meng

Zheng Gu

Jiong Lu

Affiliations

Soon will be listed here.

Abstract

Background: Retinal vein occlusion (RVO) is a common retinal vascular disease and it is one of the most frequently reported causes of visual damage and blindness in the elderly. The current study investigated the potential association between antiphospholipid antibodies (APLA) and RVO risk by conducting a meta-analysis of case-control studies.

Methods: A systematic literature search of Pubmed and Embase databases was conducted in August 1st, 2014. Odds ratios (ORs) were used to evaluate the associations between APLA and the incidence of RVO. A random-effects model was obtained for the quantitative synthesis.

Results: A total of 11 studies were included in this meta-analysis. A meta-analysis of all studies assessing the risk of RVO revealed that APLA was associated with a statistically increased risk of RVO incidence (OR = 5.18, 95% CI = [3.37, 7.95]). The association between anticardiolipin antibodies (ACA) and the risk of RVO was significant (n =8, OR = 4.59, 95% CI = [2.75, 7.66]). However, the association between lupus anticoagulants (LA) and risk of RVO was non-significant (n = 5, OR = 3.90, 95% CI = [0.99, 15.37]). No significant publication bias was found in the 11 selected studies.

Conclusion: APLA was significantly associated with the risk of RVO. Advanced analyses showed that ACA rather than LA affected the risk of RVO. Additional well-designed and well-conducted epidemiological studies are required to further our understanding of the relationship between APLA and RVO risk.

Citing Articles

Expression profiling of Nuclear Factor-Y (NF-Y) transcription factors during dehydration and salt stress in finger millet reveals potential candidate genes for multiple stress tolerance.

Rani V, Rana S, Muthamilarasan M, Joshi D, Yadav D Planta. 2024; 259(6):136.

PMID: 38679693 DOI: 10.1007/s00425-024-04417-y.

"Millet Models" for harnessing nuclear factor-Y transcription factors to engineer stress tolerance in plants: current knowledge and emerging paradigms.

Rani V, Joshi D, Joshi P, Singh R, Yadav D Planta. 2023; 258(2):29.

PMID: 37358736 DOI: 10.1007/s00425-023-04186-0.

The role of residual renal function on potassium intake and excretion in patients on peritoneal dialysis.

Claudino G, Ramos C, de Andrade L, Pereira N, Teixeira R, Muniz G Int Urol Nephrol. 2023; 55(6):1549-1556.

PMID: 36648740 DOI: 10.1007/s11255-023-03462-y.

Ocular Manifestations Related to Antibodies Positivity and Inflammatory Biomarkers in a Rheumatological Cohort.

Cifuentes-Gonzalez C, Uribe-Reina P, Reyes-Guanes J, Munoz-Ortiz J, Munoz-Vargas P, Rojas-Carabali W Clin Ophthalmol. 2022; 16:2477-2490.

PMID: 35971506 PMC: 9375558. DOI: 10.2147/OPTH.S361243.

Purification and biochemical characterization of a new thermostable laccase from Enterococcus faecium A2 by a three-phase partitioning method and investigation of its decolorization potential.

Birge A, Alcicek E, Baltaci M, Sisecioglu M, Adiguzel A Arch Microbiol. 2022; 204(8):533.

PMID: 35906438 DOI: 10.1007/s00203-022-03054-x.

References

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

Glueck C, Hutchins R, Jurantee J, Khan Z, Wang P . Thrombophilia and retinal vascular occlusion. Clin Ophthalmol. 2012; 6:1377-84. PMC: 3437951. DOI: 10.2147/OPTH.S34627. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Maaroufi R, Hamdi R, Jmili N, Ghorbal M, Hamida B, Mahjoub T . Antiphospholipid syndrome and retinal vein occlusion in adults. East Mediterr Health J. 2005; 10(4-5):627-32. View

Adamczuk Y, Iglesias Varela M, Martinuzzo M, Cerrato G, Forastiero R . Central retinal vein occlusion and thrombophilia risk factors. Blood Coagul Fibrinolysis. 2002; 13(7):623-6. DOI: 10.1097/00001721-200210000-00007. View

Kolar P . Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014; 2014:724780. PMC: 4070325. DOI: 10.1155/2014/724780. View

Abayi D, Giraud J, Fenolland J, El Asri F, Sendon D, May F . [A rare trauma-associated cause of central retinal vein occlusion in a young subject]. J Fr Ophtalmol. 2012; 35(6):426-31. DOI: 10.1016/j.jfo.2011.11.008. View

Braithwaite T, Nanji A, Lindsley K, Greenberg P . Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014; (5):CD007325. PMC: 4292843. DOI: 10.1002/14651858.CD007325.pub3. View

Plunkett O, Lip P, Lip G . Atrial fibrillation and retinal vein or artery occlusion: looking beyond the eye. Br J Ophthalmol. 2014; 98(9):1141-3. DOI: 10.1136/bjophthalmol-2013-304646. View

10.

Mrad M, Fekih-Mrissa N, Wathek C, Rannen R, Gabsi S, Gritli N . Thrombophilic risk factors in different types of retinal vein occlusion in Tunisian patients. J Stroke Cerebrovasc Dis. 2014; 23(6):1592-8. DOI: 10.1016/j.jstrokecerebrovasdis.2013.12.048. View

11.

Van Cott E, Laposata M, Hartnett M . Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood Coagul Fibrinolysis. 2004; 15(5):393-7. DOI: 10.1097/01.mbc.0000114442.59147.8d. View

12.

Glacet-Bernard A, Bayani N, Chretien P, Cochard C, Lelong F, Coscas G . Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients. Arch Ophthalmol. 1994; 112(6):790-5. DOI: 10.1001/archopht.1994.01090180088041. View

13.

Pasoto S, Chakkour H, Natalino R, Viana V, Bueno C, Lianza A . Lupus anticoagulant: a marker for stroke and venous thrombosis in primary Sjögren's syndrome. Clin Rheumatol. 2012; 31(9):1331-8. DOI: 10.1007/s10067-012-2019-z. View

14.

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

15.

Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai A . Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost. 2001; 86(3):772-6. View

16.

de Medeiros D, Silva C, Bueno C, Ribeiro A, Viana V, Freire Carvalho J . Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production?. Lupus. 2014; 23(13):1412-6. DOI: 10.1177/0961203314540351. View

17.

Dong N, Wang B, Chu L, Xiao L . Plasma homocysteine concentrations in the acute phase after central retinal vein occlusion in a Chinese population. Curr Eye Res. 2013; 38(11):1153-8. DOI: 10.3109/02713683.2013.809124. View

18.

Fiebai B, Ejimadu C, Komolafe R . Incidence and risk factors for retinal vein occlusion at the University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria. Niger J Clin Pract. 2014; 17(4):462-6. DOI: 10.4103/1119-3077.134040. View

19.

Ali O, Slagle W, Hamp A . Case report: branch retinal vein occlusion and primary antiphospholipid syndrome. Optometry. 2011; 82(7):428-33. DOI: 10.1016/j.optm.2010.07.032. View

20.

cernak M, Struharova K . Current therapy for retinal vein occlusion. Bratisl Lek Listy. 2012; 113(4):228-31. DOI: 10.4149/bll_2012_052. View